Investment
Features
FeesSafety
Academy
More
Pluang+

Compare GXO Logistics Inc (GXO) vs Heron Therapeutics Inc (HRTX) Price & Performance

GXO Logistics IncTrade
Heron Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

GXO Logistics Inc vs Heron Therapeutics Inc — how do they compare? GXO Logistics Inc trades at $46.56 (market cap $5.32B), while Heron Therapeutics Inc trades at $0.41 (market cap $68.01M). The key difference: GXO Logistics Inc is far larger — about 78.2× Heron Therapeutics Inc's market cap, and Heron Therapeutics Inc is more actively traded (1,891,941 versus 1,255,816). Which is the better fit depends on your goals — on Pluang, investors hold GXO Logistics Inc for 28 Days and Heron Therapeutics Inc for 35 Days on average.

GXOHRTX
Market Cap
$5.32B$68.01M
Volume
1,255,8161,891,941
Sector
IndustrialsHealth
52-Week High
$65.59$1.49
52-Week Low
$44.17$0.27
Typical Hold Time
28 Days35 Days
Enterprise Value
$10.67B$174.75M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

GXO Logistics Inc

GXO Logistics trades at $46.36, up 0.8% with neutral technical indicators. The company shows improving fundamentals with three consecutive quarterly EPS beats and strong analyst support (88.9% buy ratings). Recent strategic partnerships with Columbia Sportswear and aerospace/defense expansion signal growth potential, though margins remain thin with net income at 0.96%.

GXO presents a compelling growth story with 42% upside to consensus price target of $66.67. Key catalysts include logistics industry recovery and operational efficiency initiatives, but investors face margin pressure risks and competitive threats in the contract logistics space that could limit profitability expansion.

Heron Therapeutics Inc

HRTX trades at $0.3582, down 8.15% today, with a bullish technical signal from moving averages but mixed earnings. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates, continuing a trend of net losses. Analyst sentiment remains strongly positive with 89% buy ratings, though Zacks issued a Strong Sell rating in July 2026.

The outlook hinges on revenue stabilization and path to profitability. Investment opportunity lies in analyst optimism and product sales growth, but risks include persistent losses, high valuation multiples, and competitive pressures in the biotechnology sector.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

GXO

No sentiment data available yet.

HRTX
43% Buy57% Sell
Avg holding period · 35 Days

Top news

Latest headlines on both assets

About GXO Logistics Inc

GXO is the world's largest pure-play contract logistics provider. It offers cutting-edge supply chain solutions, including automated warehousing and fulfillment, for global blue-chip companies.

Read more on GXO →

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX →